Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors
Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.
You may also be interested in...
New products continue to drive Lilly’s revenue growth and the company expects that to remain the case even if the final Phase III trial for Alzheimer’s candidate solanezumab fails later this year.
Johnson & Johnson and Roche launched the big pharma quarterly reporting season. Next up are Novartis, Lilly, Merck, Bayer, GSK, Bristol-Myers Squibb, Amgen and Sanofi. Scrip offers some key points to watch for.
Analysis by the Institute for Clinical and Economic Review finds Remicade offers the 'greatest benefit per dollar spent' in treating psoriasis compared to other biologics, which are considered 'moderately” cost effective.